Evaluation of the Safety and Efficacy of Late-onset Pompe Disease Gene Therapy Drug

NCT06391736 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

33

Enrollment

INDUSTRY

Sponsor class

Conditions

Pompe Disease (Late-onset)

Interventions

GENETIC: GC301

Sponsor

GeneCradle Inc